Abstract
Hsp90 is a chaperone with important roles in maintaining transformation and in elevating the survival and growth potential of cancer cells. Activation of signaling pathways mediated by Hsp90 protein clients is necessary for cell proliferation, regulation of cell cycle progression and apoptosis. Additionally, gain-of-function mutations responsible for transformation often require Hsp90 for the maintenance of their folded, functionally active conformations. These characteristics promise Hsp90 as an important target in cancer therapy and prompt for the identification, development and clinical translation of small molecule inhibitors of the chaperone. This review intends to update the reader on the status of several existing and emerging classes of direct inhibitors of Hsp90 ATPase activity.
Keywords: 17AAG, 17DMAG, PU-class Hsp90 inhibitors, radicicol and derivatives, 3,4-diarylpyrazoles, anti-cancer therapeutics
Anti-Cancer Agents in Medicinal Chemistry
Title: Emerging Hsp90 Inhibitors: From Discovery to Clinic
Volume: 6 Issue: 1
Author(s): G. Chiosis, A. Rodina and K. Moulick
Affiliation:
Keywords: 17AAG, 17DMAG, PU-class Hsp90 inhibitors, radicicol and derivatives, 3,4-diarylpyrazoles, anti-cancer therapeutics
Abstract: Hsp90 is a chaperone with important roles in maintaining transformation and in elevating the survival and growth potential of cancer cells. Activation of signaling pathways mediated by Hsp90 protein clients is necessary for cell proliferation, regulation of cell cycle progression and apoptosis. Additionally, gain-of-function mutations responsible for transformation often require Hsp90 for the maintenance of their folded, functionally active conformations. These characteristics promise Hsp90 as an important target in cancer therapy and prompt for the identification, development and clinical translation of small molecule inhibitors of the chaperone. This review intends to update the reader on the status of several existing and emerging classes of direct inhibitors of Hsp90 ATPase activity.
Export Options
About this article
Cite this article as:
Chiosis G., Rodina A. and Moulick K., Emerging Hsp90 Inhibitors: From Discovery to Clinic, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (1) . https://dx.doi.org/10.2174/187152006774755483
DOI https://dx.doi.org/10.2174/187152006774755483 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Osteoimmunology and Beyond
Current Medicinal Chemistry Comparative Proteomics and Bioinformatics Analysis of Tissue from Non-Small Cell Lung Cancer Patients
Current Proteomics B Cells and Beyond: Therapeutic Opportunities Targeting Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine Is Helicobacter pylori Always a "Bad Guy"?
Current Pharmaceutical Design Resveratrol as an Enhancer of Apoptosis in Cancer: A Mechanistic Review
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Bone Target Radiotracers for Palliative Therapy of Bone Metastases
Current Medicinal Chemistry Editorial [Hot Topic: Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia (Executive Editors: Francis J. Giles / Maher Albitar)]
Current Molecular Medicine GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Pharmacodynamics and Pharmacokinetics of Antifungals for Treatment of Invasive Aspergillosis
Current Pharmaceutical Design Novel HSP90 Inhibitor NVP-AUY922 Enhances the Anti-tumor Effect of Temsirolimus Against Oral Squamous Cell Carcinoma
Current Cancer Drug Targets Cancer: A Problem of Developmental Biology; Scientific Evidence for Reprogramming and Differentiation Therapy
Current Drug Targets Defining and Managing Expectations for Early Immunotherapy Cancer Trials
Reviews on Recent Clinical Trials Nuclear PI-PLCβ1 and Myelodysplastic Syndromes: Genetics and Epigenetics
Current Pharmaceutical Design The Molecular Characterization and Biological Assessment of the Leaves Extracts of Loofah Reveal their Nutraceutical Potential
Recent Patents on Food, Nutrition & Agriculture Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Clinical Presentation, Outcome and Risk Factors of Late-Onset Non- Infectious Pulmonary Complications After Allogeneic Stem Cell Transplantation
Current Stem Cell Research & Therapy Conserved Domains, Residues, WebLogo and Active Sites of Caspase- Cascades Related to Apoptotic Signaling Pathway
Current Bioinformatics An Update on the Systemic Therapy of Malignant Salivary Gland Cancers: Role of Chemotherapy and Molecular Targeted Agents
Current Medicinal Chemistry - Anti-Cancer Agents